Dalbavancin Use at a Health System Network in Compliance with a Standard Plan of Treatment for Infective Endocarditis and Osteomyelitis

Dalbavancin is a lipoglycopeptide approved for the treatment of acute bacterial skin and soft tissue infections caused by gram-positive microorganisms. Used off-label in the management of infective endocarditis in IV drug users, as well as in osteomyelitis infections. Extremely long half-life of greater than a week. Potential cost-effective option for susceptible gram-positive infections and increased patient compliance.